16
Participants
Start Date
July 18, 2024
Primary Completion Date
August 3, 2024
Study Completion Date
August 3, 2024
15 mg DA-302168S tablet
"Qualified subjects will be randomly assigned to one of two dosing sequences in a 1:1 ratio. Either DA-302168S tablet with food on Day 1 and DA-302168S tablet without food on Day 6 (treatment sequence fed/fasted), or DA-302168S tablet without food on Day 1 and DA-302168S tablet with food on Day 6 (treatment sequence fasted/fed).~Each administration sequence consists of two cycles, with one administration per cycle and a 5-day washout period between each administration."
Gulou Hospital Affiliated to Nanjing Medical University, Nanjing
Lead Sponsor
Chendu DIAO Pharmaceutical Group CO., LTD.
INDUSTRY